Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018

Size: px
Start display at page:

Download "Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018"

Transcription

1 Automated manufacture of T-cell immunotherapies using gamma retroviral transduction Lee Markwick, PhD AMC, Manchester March 2018

2 Automated generation of CAR T cells Starting material d0 T cell enrichment and activation d1 Transduction d2-10 Expansion d10-14 Final product (max of 14 days) 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 2

3 CliniMACS Prodigy TCT Process Cell selection Cell activation Cell transduction Cell expansion Final formulation IPC/QC CliniMACS Buffer MACS GMP TransAct GMP Lentiviral Vector MACS GMP TexMACS CliniMACS Reagents: CD4 / CD8, CD62L MACS GMP TexMACS CliniMACS Prodigy TS 520 CliniMACS Prodigy TCT Process for RV and LV MACS GMP IL-2, IL-7, IL-15, IL-21 flow reagents and REA antibodies 7 color immunophenotyping kit MACSPlex Cytokine Kit Rapid Cytokine Inspector Kit 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 3

4 TCT process - robust and reproducible with pts material Cell selection Cell activation Cell transduction Cell expansion Final formulation Robust expansion of healthy material (n=12) and pts material (n=6) Good viability of healthy material (n=12) and pts material (n=6) Patient material T cells CAR + T cells Melanoma 2.35E9 1.38E9 Lymphoma 3.68E9 1.54E9 Lymphoma 3.31E9 - Lymphoma frozen 4.90E9 1.09E9 Lymphoma frozen 3.20E9 0.72E9 E.g. dose: 10 7 CAR + T cells / kg (130kg patient) 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 4

5 TCT process - robust and reproducible in serum free conditions Cell selection Cell activation Cell transduction Cell expansion Final formulation 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 5

6 Volume reduction Addition RV + enhancer Spin 400g, 32 C Culture wash Start shaking New Activities to enable TCT for retroviral vector TCT Retro Enrichment Volume chamber Activation in 70 ml day h incubation time 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 6

7 Retroviral transduction Cell selection Cell activation Cell transduction Cell expansion Final formulation IPC/QC Vectofusin-1 Transduction enhancer Fully synthetic, non toxic, soluble peptide No pre-treatment/coating needed - added directly to viral supernatant! Straight forward and simple protocol Available in research and GMP grade 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 7

8 Retroviral Transduction Cell selection Cell activation Cell transduction Cell expansion Final formulation 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 8

9 Cellular composition of final product Cell selection Cell activation Cell transduction Cell expansion Final formulation 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 9

10 Functionality: Killing of CD20+ JeKo-1 cells Cytokine secretion profiles Healthy donor Cytotoxicity Healthy donor Patient material Patient material Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. 8th March 2018 Page 10

11 Robust manufacturing of polyfunctional gene-engineered T cells: In vivo mouse model 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 11

12 Cell Manufacturing Centres 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 12

13 Integral Single Unit Manufacturing Parallel Manufacturing. Instantly scalable More devices, more products Simplicity at Scale. One process, one device Complexity Minimisation: Process steps Connections Device upkeep & maintenance 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 13

14 Facility Considerations (Layouts for 2000 patients p.a.) David James Cell Gene Therapy Insights 2017;3(4). 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 14

15 CliniMACS Prodigy in clinical trial and licensed commercial product 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 15

16 Miltenyi Biotec manufacturing suite 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 16

17 Automation & Operation March 13, 2018 Jason Jones, Miltenyi Biotec Ltd Page 17

18 Parallel manufacturing of cell and gene therapy products March 13, 2018 Page 18

19 Not just CAR T-cells Blood Leukapheresis Cell selection Cell activation Cell transduction Cell expansion Cell formulation Patient Donor / patient MoDC CAR T cells Treg cells Antigen-specific T cells Gene-modified stem cells TCR T cells NK cells MSCs 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 19

20 Your trusted partner for cell and gene therapy 8th March 2018 Automated manufacture of T-cell immunotherapies - Lee Markwick Ph. D. Page 20

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples ISCT North America 216 Regional Meeting Nadine Mockel-Tenbrinck Miltenyi Biotec GmbH Macrophage Tumour

More information

Changing the way of generating engineered T cells. CliniMACS Prodigy T Cell Transduction Process

Changing the way of generating engineered T cells. CliniMACS Prodigy T Cell Transduction Process Changing the way of generating engineered T cells CliniMACS Prodigy T Cell Transduction Process CliniMACS Prodigy T Cell Transduction Process It is happening a new era of cell therapy Chimeric antigen

More information

Efficient T cell activation and expansion. T Cell TransAct

Efficient T cell activation and expansion. T Cell TransAct Efficient T cell activation and expansion T Cell TransAct Introducing your new solution in T cell activation What is T Cell TransAct? This ready-to-use reagent provides an innovative method for physiological

More information

Bioassays for Quality Control of Cell & Gene Therapy Products

Bioassays for Quality Control of Cell & Gene Therapy Products Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen

More information

ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection

ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin

More information

Advances in Immunotherapy for Lymphoma. Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow

Advances in Immunotherapy for Lymphoma. Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow Advances in Immunotherapy for Lymphoma Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow The immune system and cancer Immunotherapies available for lymphoma Upcoming immunotherapy clinical trials

More information

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines

More information

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy

More information

In vitro human regulatory T cell suppression assay

In vitro human regulatory T cell suppression assay Human CD4 + CD25 + regulatory T cell isolation, in vitro suppression assay and analysis In vitro human regulatory T cell suppression assay Introduction Regulatory T (Treg) cells are a subpopulation of

More information

Immunotherapy on the Horizon: Adoptive Cell Therapy

Immunotherapy on the Horizon: Adoptive Cell Therapy Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest

More information

Choosing Optimal Viral Vector for T-cell Transduction. Viral vectors for blood cells

Choosing Optimal Viral Vector for T-cell Transduction. Viral vectors for blood cells Choosing Optimal Viral Vector for T-cell Transduction Max Mamonkin, PhD Center for Cell and Gene Therapy Baylor College of Medicine PACT Webinar Nov 08, 2018 Viral for blood cells Short/long term gene

More information

In vitro human regulatory T cell expansion

In vitro human regulatory T cell expansion - 1 - Human CD4 + CD25 + regulatory T cell isolation, Workflow in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation of T

More information

Journal of Oral & Dental Health

Journal of Oral & Dental Health Research Article Efficacy of Car T-Cell Therapy in Head and Neck Cancers- A Meta-Analysis Avisesh Manohar 1 *, Athira PM 1, Gaurav 2 and Shibu 3 Journal of Oral & Dental Health ISSN: 2573-8224 1 House

More information

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models Yuki Kagoya,, Cheryl H. Arrowsmith, Naoto Hirano J Clin Invest. 2016;126(9):3479-3494. https://doi.org/10.1172/jci86437.

More information

In vitro human regulatory T cell expansion

In vitro human regulatory T cell expansion - 1 - Human CD4 + CD25 + CD127 dim/- regulatory T cell Workflow isolation, in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Cultivated anti-aspergillus T H 1 Cells. Thomas Lehrnbecher Pediatric Hematology and Oncology Frankfurt/Main, Germany

Cultivated anti-aspergillus T H 1 Cells. Thomas Lehrnbecher Pediatric Hematology and Oncology Frankfurt/Main, Germany Cultivated anti-aspergillus T H 1 Cells Thomas Lehrnbecher Pediatric Hematology and Oncology Frankfurt/Main, Germany Invasive fungal infection after allogeneic SCT Incidence of proven invasive fungal infections

More information

Estimand and analysis considerations of phase 3 clinical trials involving CAR-T A case study in lymphoma

Estimand and analysis considerations of phase 3 clinical trials involving CAR-T A case study in lymphoma Estimand and analysis considerations of phase 3 clinical trials involving CAR-T A case study in lymphoma Michael Yiyun Zhang, on behalf of Novartis Team 2018 ASA Biopharmaceutical Section Regulatory-Industry

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins

More information

All you need for your T cell research

All you need for your T cell research All you need for your T cell research Gentle sample preparation Accurate cell separation Optimized cell culture Precise flow cytometry Products for isolation of mouse T cells T cells CD3ε MicroBead Kit

More information

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central

More information

Fast and Easy Isolation of T Cells

Fast and Easy Isolation of T Cells Fast and Easy Isolation of T Cells Isolate T Cells In As Little As 25 Minutes Isolate whole T cell populations as well as various T cell subsets with high purity and recovery using the fast and easy T

More information

Melanoma Bridge Meeting

Melanoma Bridge Meeting Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose

More information

Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator

Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator INCUCYTE LIVE-CELL ANALYSIS SYSTEM Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator See what your cells are doing and when they

More information

The Effects of Induced Aggregation of IgG and Insulin Preparations on In Vitro T Cell Stimulation

The Effects of Induced Aggregation of IgG and Insulin Preparations on In Vitro T Cell Stimulation Website home page picture here The Effects of Induced Aggregation of IgG and Insulin Preparations on In Vitro T Cell Stimulation 2 nd EIP Symposium 17 th -19 th November 29 Immune Responses to Protein

More information

Excerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴

Excerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴ Excerpt from MCS&more Vol 17 1/2016 Dendritic cells pulsed with induce both OV-specific CD4 + and CD8 + T cells and cause antitumor effects in a mouse model of lymphoma Kenji Miki¹, Koji Nagaoka¹, Hermann

More information

Abstract #163 Michael Kalos, PhD

Abstract #163 Michael Kalos, PhD LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract

More information

IFN-γ Secretion Assay Detection Kit (PE) human

IFN-γ Secretion Assay Detection Kit (PE) human Miltenyi Biotec GmbH Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach, Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macs@miltenyibiotec.de Miltenyi Biotec Inc. 12740 Earhart Avenue Auburn CA 95602,

More information

Regulatory T cell research

Regulatory T cell research Regulatory T cell research Unique kits for cell isolation Harmonized cell culture and expansion tools Convenient functional assay tools Reliable flow cytometry analysis Introduction The complete workflow

More information

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res

More information

Masashi Takahara,* Manami Miyai,* Mai Tomiyama,* Masato Mutou,* Andrew J. Nicol, and Mie Nieda*,1

Masashi Takahara,* Manami Miyai,* Mai Tomiyama,* Masato Mutou,* Andrew J. Nicol, and Mie Nieda*,1 Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8 T cells via V 9 T cell activation Masashi Takahara,* Manami Miyai,* Mai Tomiyama,*

More information

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205 AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING

More information

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells Tischer et al. Journal of Translational Medicine (2014) 12:336 DOI 10.1186/s12967-014-0336-5 RESEARCH Open Access Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors

More information

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Bead Based Assays for Cytokine Detection

Bead Based Assays for Cytokine Detection Bead Based Assays for Cytokine Detection September 27, 2014 6 th EFIS-EJI South East European Immunology School SEEIS 2014 Timisoara, Romania The Cells of the Immune System The Immune Reaction (Th2) (Th1)

More information

T H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells

T H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells A complete workflow for cell preparation, isolation, polarization and analysis T H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells Introduction Workflow CD4 + T helper (T H) cells play a

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize

More information

Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes

Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes Joint Lab Meeting 03/03/2015 Human Innate Lymphoid Cells: crosstalk with CD4 + regulatory T cells and role in Type 1 Diabetes Caroline Raffin Bluestone Lab ILCs: Definition - Common lymphoid progenitor

More information

US Regulatory Considerations for Therapeutic Cancer Vaccines

US Regulatory Considerations for Therapeutic Cancer Vaccines US Regulatory Considerations for Therapeutic Cancer Vaccines Peter Bross, M.D., Team Leader, Clinical Oncology, FDA Center for Biologics Evaluation and Research 1 Immune Therapies: The Future Is Now Tuesday,

More information

Yescarta (axicabtagene ciloleucel)

Yescarta (axicabtagene ciloleucel) Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider

More information

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone

More information

Tonic CAR signaling in T cells:

Tonic CAR signaling in T cells: Tonic CAR signaling in T cells: toxicities and ways to manage Max Mamonkin, PhD CAR-TCR Summit 9/6/217 Boston, MA CAR signaling Antige n Target cell CAR Signal 2 T cell Signal 1 Clustering Signaling Tonic

More information

How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach

How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about T cell function was known, but the receptor genes had not been identified

More information

A second type of TCR TCR: An αβ heterodimer

A second type of TCR TCR: An αβ heterodimer How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

Transforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017

Transforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017 Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy

More information

Clinical research Treg cell manufacture CliniMACS Cell Separation System and MACS GMP Products

Clinical research Treg cell manufacture CliniMACS Cell Separation System and MACS GMP Products Clinical research Treg cell manufacture CliniMACS Cell Separation System and MACS GMP Products Treg cell enrichment and depletion MACS GMP Fluorescent Antibodies for flow sorting Treg cell expansion Analysis

More information

Chapter 7 Conclusions

Chapter 7 Conclusions VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy

More information

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our

More information

Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303

Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 Carolyn Keever-Taylor, Steven M Devine, Robert J Soiffer, Shelly L Carter, Marcelo Pasquini,

More information

Gianpietro Dotti Baylor College of Medicine, Houston TX, USA

Gianpietro Dotti Baylor College of Medicine, Houston TX, USA CARs in the clinic: first efficacy reports and concerns about safety Gianpietro Dotti Baylor College of Medicine, Houston TX, USA Adoptive Immunotherapy of Gene Modified T Cells T lymphocytes 1 Blood draw

More information

THE PHASE I/II CLINICAL TRIAL IN PATIENTS WITH BLADDER CANCER

THE PHASE I/II CLINICAL TRIAL IN PATIENTS WITH BLADDER CANCER HAMLET PHARMA NEWSLETTER THE PHASE I/II CLINICAL TRIAL IN PATIENTS WITH BLADDER CANCER The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin

More information

NATURAL KILLER T CELLS EBOOK

NATURAL KILLER T CELLS EBOOK 08 April, 2018 NATURAL KILLER T CELLS EBOOK Document Filetype: PDF 90.41 KB 0 NATURAL KILLER T CELLS EBOOK Natural killer T cells (NK T cells) are a type of lymphocyte, or white blood cell. Natural killer

More information

Supplementary Data. Treg phenotype

Supplementary Data. Treg phenotype Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see

More information

Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells

Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Gavin M. Mason, Sarah Jackson, Georgina Okecha, Emma Poole, J. G. Patrick Sissons, John Sinclair,

More information

Modulation of immunogenicity by engineered antigen-specific regulatory T cells: Fighting fire with fireman or police CARs

Modulation of immunogenicity by engineered antigen-specific regulatory T cells: Fighting fire with fireman or police CARs Modulation of immunogenicity by engineered antigen-specific regulatory T cells: Fighting fire with fireman or police CARs David W. Scott Department of Medicine Uniformed Services University of the Health

More information

Exploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer

Exploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer Exploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer G.L.Owens 1,2, V.Sheard 2, M.Price 1, D.E.Gilham 2, R.J.Edmondson 1 1 Gynaecological Oncology Research

More information

Stem Cell Sources 2/22/13. Cellular Therapy Today and Tomorrow. Cellular Therapy in HCT. Bone Marrow

Stem Cell Sources 2/22/13. Cellular Therapy Today and Tomorrow. Cellular Therapy in HCT. Bone Marrow 2/22/13 Cellular Therapy Today and Tomorrow Robert S. Negrin, MD Division Chief, Stanford Bone and Marrow Transplant Program Professor of Medicine Cellular Therapy in Clinical Medicine Established Hematopoietic

More information

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M)

Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) OFF-THE-SHELF T CELL THERAPY FOR CANCER PATIENTS FOLLOWING STEM CELL TRANSPLANT Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) Ann M.

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

Start your T cell research right

Start your T cell research right Cell Isolation and Expansion Start your T cell research right Dynabeads tube-based cell isolation Cell Isolation and Expansion When you need healthy, pure, and viable T cells Dynabeads for human and mouse

More information

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?

More information

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response

More information

Automated manufacturing of CAR-T cells for Adoptive Immunotherapy using

Automated manufacturing of CAR-T cells for Adoptive Immunotherapy using Title page Automated manufacturing of CAR-T cells for Adoptive Immunotherapy using CliniMACS Prodigy Running Title (max 50 characters): Automated T cell transduction for GMP-manufacturing Ulrike Mock 1,

More information

Reporter Gene Immunotherapy Bioassays

Reporter Gene Immunotherapy Bioassays Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation

More information

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014 Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus

More information

DEVELOPMENT OF CELLULAR IMMUNOLOGY

DEVELOPMENT OF CELLULAR IMMUNOLOGY DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer

More information

Enhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington

Enhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma

More information

Clinical Translation of Immunotherapy using WT1 and CMV specific TCR Gene Transfer

Clinical Translation of Immunotherapy using WT1 and CMV specific TCR Gene Transfer Clinical Translation of Immunotherapy using WT1 and CMV specific Gene Transfer Dr Emma C Morris Reader, Dept of Immunology, UCL Consultant Haematologist (BMT), UCLH and RFH ISCT, 2/5/211 Gene Transfer

More information

Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice

Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25

More information

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice

More information

NT PLANT QUARANTINE & BIOSECURITY GUIDANCE NOTE. NUMBER 3 USE OF Phytophthora LATERAL FLOW DEVICES (LFDs)

NT PLANT QUARANTINE & BIOSECURITY GUIDANCE NOTE. NUMBER 3 USE OF Phytophthora LATERAL FLOW DEVICES (LFDs) NT PLANT QUARANTINE & BIOSECURITY GUIDANCE NOTE NUMBER 3 USE OF Phytophthora LATERAL FLOW DEVICES (LFDs) 1.0 Background How can they help us? Symptoms of diseases caused by Phytophthora species can often

More information

Following T-cell activation and differentiation with HTRF reagents: IL-2, IFN-γ and IL-17

Following T-cell activation and differentiation with HTRF reagents: IL-2, IFN-γ and IL-17 Following T-cell activation and differentiation with HTRF reagents: IL-2, IFN-γ and IL-17 4 th HTRF Symposium for Drug Discovery Avignon, Sept. 24-26, 28 Introduction: T-cells have effector and helper

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

Exosomes Immunocapture and Isolation Tools: Immunoplates

Exosomes Immunocapture and Isolation Tools: Immunoplates Product Insert Exosomes Immunocapture and Isolation Tools: Immunoplates HBM-POF-##/## HBM-POC-##/## Overall Exosome capture from Biological fluids (plasma, urine) Overall Exosome capture from Cell culture

More information

Technical Bulletin No. 172

Technical Bulletin No. 172 CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,

More information

Living Immunotherapies. Corporate Presentation OCTOBER 2018

Living Immunotherapies. Corporate Presentation OCTOBER 2018 Living Immunotherapies Corporate Presentation OCTOBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

In vitro expansion of mouse CD4 + T cells

In vitro expansion of mouse CD4 + T cells Direct ex vivo isolation, cultivation and expansion of CD4 + T cells from mouse spleen In vitro expansion of mouse CD4 + T cells Introduction CD4 + T helper (TH) cells play a central role in the adaptive

More information

colorimetric sandwich ELISA kit datasheet

colorimetric sandwich ELISA kit datasheet colorimetric sandwich ELISA kit datasheet For the quantitative detection of human IL5 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity

More information

Corporate Deck JP Morgan January 2019

Corporate Deck JP Morgan January 2019 Corporate Deck JP Morgan 2019 January 2019 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Living immunotherapies. Corporate Presentation

Living immunotherapies. Corporate Presentation Living immunotherapies Corporate Presentation MAY 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our

More information

Rapid antigen-specific T cell enrichment (Rapid ARTE)

Rapid antigen-specific T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role

More information

Primary Adult Naïve CD4+ CD45RA+ Cells. Prepared by: David Randolph at University of Alabama, Birmingham

Primary Adult Naïve CD4+ CD45RA+ Cells. Prepared by: David Randolph at University of Alabama, Birmingham Primary Adult Naïve CD4+ CD45RA+ Cells Prepared by: David Randolph (drdrdr@uab.edu) at University of Alabama, Birmingham Goal: To obtain large numbers of highly pure primary CD4+ CD45RO- CD25- cells from

More information

Novel Approaches to CAR-T Cell Platform

Novel Approaches to CAR-T Cell Platform Novel Approaches to CAR-T Cell Platform Vita Golubovskaya, Ph.D. Director, R&D Promab Biotechnologies 3 rd CAR-TCR Summit 2017 S E P T E M B E R 5-7 B O S T O N Novel Approaches To CAR-T Cell Platform

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

The broadest portfolio for your T cell research

The broadest portfolio for your T cell research quick guide The broadest portfolio for your T cell research Sample preparation Cell separation Cell culture Flow cytometry Mouse T cells Overview CD4 + T cell subsets Polarization reagents Naive CD4 +

More information

Cell Migration and Invasion Assays INCUCYTE LIVE-CELL ANALYSIS SYSTEM. Real-time automated measurements of cell motility inside your incubator

Cell Migration and Invasion Assays INCUCYTE LIVE-CELL ANALYSIS SYSTEM. Real-time automated measurements of cell motility inside your incubator Cell Migration and Invasion Assays INCUCYTE LIVE-CELL ANALYSIS SYSTEM Real-time automated measurements of cell motility inside your incubator See the whole story Real-time cell motility visualization and

More information

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation

More information

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009 T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells

More information

Dendritic Cell-Based Immunotherapy Vaccines for Melanoma and Hepatocellular Cancer

Dendritic Cell-Based Immunotherapy Vaccines for Melanoma and Hepatocellular Cancer Dendritic Cell-Based Immunotherapy Vaccines for Melanoma and Hepatocellular Cancer Lisa H. Butterfield, Ph.D. Assistant Professor of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute

More information

CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 +

CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 + Supplements Supplemental Materials and Methods Depletion of CD25 + T-cells from PBMC. Fresh or HD precultured PBMC were stained with the conjugate CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads

More information

xcelligence Real-Time Cell Analyzers

xcelligence Real-Time Cell Analyzers xcelligence Real-Time Cell Analyzers Application Note No. 18 Evaluating Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin Introduction A growing understanding of the molecular interactions

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology

More information

March Corporate Presentation

March Corporate Presentation March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information